CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, S.-P.
Right arrow Articles by Huang, C.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, S.-P.
Right arrow Articles by Huang, C.-H.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 2217-2224, December 2004
© 2004 American Association for Cancer Research

p53 Codon 72 and p21 Codon 31 Polymorphisms in Prostate Cancer

Shu-Pin Huang1, Wen-Jeng Wu1, Wun-Shaing Wayne Chang4, Ming-Tsang Wu2,3, Yun-Yun Chen2, Yun-Ju Chen2, Chia-Cheng Yu5, Tony T. Wu5, Ying-Huei Lee6, Jong-Khing Huang5 and Chun-Hsiung Huang1

1 Department of Urology, 2 Graduate Institute of Occupational Safety and Health, Departments of 3 Occupational Medicine and Family Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China; 4 President's Laboratory National Health Research Institutes, Taipei, Taiwan, Republic of China; 5 Department of Surgery, Division of Urology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, Republic of China; and 6 Department of Urology, Chi Mei Medical Center, Tainan, Taiwan, Republic of China

Requests for reprints:M-T. Wu, Graduate Institute of Occupational Safety and Health, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung, Taiwan 807, Republic of China. Phone: 886-7312-1101, ext. 2315; Fax: 886-7322-1806; E-mail: mingtsangwu{at}yahoo.com


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The tumor suppressor gene p53 and its downstream effector p21 are thought to play major roles in the development of human malignancy. Polymorphic variants of p53 at codon 72, and p21 at codon 31, have been found to be associated with cancer susceptibility, but few studies have investigated their effect on prostate cancer risk. In this case-control study, we investigated the association of p53 codon 72 and p21 codon 31 polymorphisms with prostate cancer risk in a Taiwanese population. In total, 200 patients with prostate cancer, 247 age-matched male controls, and 181 non–age-matched symptomatic benign prostatic hyperplasia (BPH; American Urological Association symptom score ≥ 8 and prostate volume > 20 gm) recruited from two medical centers in southern Taiwan were genotyped. Overall, we found no significant association between p53 polymorphism and risk of prostate cancer. However, for p21 polymorphism, the frequencies of p21 Ser/Ser, Ser/Arg and Arg/Arg were 52 (26.0%), 85 (42.5%), 63 (31.5%) in case patients, 48 (26.5%), 82 (45.3%), 51 (28.2%) in BPH patients, and 76 (30.8%), 119 (48.2%), 52 (21.1%) in controls, respectively. Among the prostate cancer cases and controls, subjects with Arg/Arg genotype were found to have a 1.78-fold increased risk [95% confidence interval (CI), 1.06-3.01] of developing prostate cancer compared with those having the Ser/Ser genotype, after adjusting for other potential covariates. This significant association was slightly stronger [odds ratio (OR), 2.13; 95% CI, 1.16-3.92] in younger men (≤ 72 years; n = 99 and 126 for cases and controls, respectively) and correlated with localized disease stage (OR, 1.96; 95 % CI, 1.15-3.35) and moderately differentiated prostate cancer (OR, 2.04; 95% CI, 1.17-3.53). In addition, the Arg/Arg genotype was associated with BPH risk in those with large prostate volumes (> 50 mL) compared with those having the Ser/Ser genotype [OR, 2.29; 95% CI, 1.07-4.98]. Our findings suggest that the p21 codon 31 polymorphism may be associated with the development of prostate enlargement and cancer.

Key Words: p53 • p21 • genetic polymorphism • prostate cancer • benign prostatic hyperplasia


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The p53 tumor suppressor gene (p53), located on chromosome 17p13, is one of the most commonly mutated genes in all types of human cancer (1, 2). In prostate cancer, mutations of this gene are frequently seen in both germ line and somatic forms (3, 4). p53 protein exhibits a common polymorphism at amino acid 72, resulting in either a proline residue (CCC) or an arginine residue (CGC) (5). An in vitro study has indicated that the p53 Arg/Arg genotype induces apoptosis with faster kinetics and suppresses transformation more efficiently than the Pro/Pro variant (6), suggesting subjects with Pro/Pro variant may be more susceptible to have cancer, probably including prostate cancer, than those with Arg/Arg genotype. However, Henner et al. (7) studied the association between this polymorphism and prostate cancer risk in 115 patients with prostate cancer and 181 controls, all Caucasians. They found that subjects with Pro/Pro, in contrast, had a significantly reduced risk of prostate cancer compared with those with Arg/Arg [odds ratios (OR), 0.14; 95% confidence interval (CI), 0.03-0.71, P = 0.017], which may be in conflict with the results from the in vitro study (6, 7). This conflicting finding could be due to the limitation of the controls not closely conforming to Hardy-Weinberg equilibrium, suggesting probable selection bias, in the study of Henner et al. (7).

Benign prostatic hyperplasia (BPH) is considered a phenotypic manifestation of loss of control in the proliferation of prostate epithelial and/or stromal cells (8). Because p53 plays an important role in the control of the cell cycle, it may be involved in the pathogenesis of BPH. Indeed, expression and mutation of p53 in BPH has been reported (9, 10); however, thus far, no one has investigated the effect of p53 codon 72 polymorphism on the development of BPH.

p21 (Waf1/CIP1), a cyclin-dependent kinase inhibitor that regulates the cell cycle, is a downstream mediator of p53 tumor suppression (11). p21 is induced by the p53 gene, thereby directly mediating p53-induced G1 arrest. Expression of p21 occurs in prostate cancer and has been associated with the clinical outcome of prostate cancer (12-16), suggesting that p21 may be an important cell cycle regulator involved in carcinogenesis and the progression of prostate cancer.

Gene alterations at p21 might be able interrupt the p53-mediated pathway of cell cycle arrest and increase susceptibility for cancer. A polymorphism in the p21 codon 31 has been found which produces a C-to-A change, causing a substitution from serine (Ser) to arginine (Arg) (17). A series of epidemiological studies found that p21 codon 31 polymorphism was associated with increased risks of lung cancer, cervical cancer, breast cancer, esophageal cancer, and nasopharyngeal cancer (18-23), although conflicting findings were still reported (24, 25). In addition, to our knowledge, no study has examined the effect of p21 codon 31 polymorphism on prostate cancer risk.

Because the gene alterations at p21 also influence the control of cell cycle, we propose that the p21 codon 31 polymorphism might also be involved in the susceptibility of BPH. Therefore, we conducted a case-control study to investigate the association of p53 codon 72 polymorphism and p21 codon 31 polymorphism with prostate cancer and BPH risks in a Taiwanese population.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Subjects
Patients with prostate cancer were recently diagnosed, between December 2000 and August 2003, and pathologically proven to have prostate adenocarcinoma at the Kaohsiung Medical University Hospital and the Kaohsiung Veterans General Hospital, two medical centers in the city of Kaohsiung in southern Taiwan. During this period, 223 patients with prostate cancer were diagnosed in these two medical centers and 200 (89.7%) of them agreed to participate in this study. Every effort was made to enroll 1 to 2 control subjects that matched each case patient in age (± 3 years) from a population of healthy men who received general health examinations in the two medical centers. If eligible controls were not available from the two medical centers, we attempted to recruit potential controls from the Kaohsiung Municipal United Hospital during the same period. The control subjects did not have significant voiding symptoms (American Urological Association symptom score < 8) (26), their prostate-specific antigen (PSA) levels were within the normal limit (< 4 ng/mL), and they had no history of prostate surgery or clinical signs of prostate hyperplasia or prostate cancer during digital rectal examination. Those who had other known malignancies were excluded.

We recruited a group of symptomatic BPH from the Kaohsiung Medical University Hospital with the criteria of significant lower urinary tract symptoms (American Urological Association symptom score ≥ 8) and prostate enlargement during digital rectal examination and ultrasonography (> 20 gm) (27, 28). Prostate volume was estimated using an ellipsoid formula (29). Those with prostate-specific antigen levels above 4 ng/mL received prostate biopsies to rule out malignancy. Finally, a total of 200 patients with prostate cancer, 181 with BPH, and 247 male controls were included in this study.

This study protocol was approved by the Institutional Review Board of the Kaohsiung Medical University Hospital. After informed consent was obtained, blood samples were collected and all subjects were asked to complete a structured questionnaire. Subjects who had smoked more than 10 cigarettes per week for at least 6 months were defined as smokers, those who had regularly chewed betel quid for at least 6 months were defined as betel quid chewers, and those who consumed beer, wine, or distilled spirits more than once a week for at least 6 months were defined as alcoholic beverage drinkers.

Based on criteria outlined by the American Joint Committee on Cancer tumor-node-metastasis classification system (American Joint Committee on Cancer Staging Manual, 5th edition, 1997), disease stage was determined by pathologic findings, pelvic computed tomography or magnetic resonance image, and radionucleotide bone scans. Pathologic grade was recorded as the Gleason score (30) and classified into three groups: well-differentiated (Gleason score 2-4), moderately differentiated (Gleason score 5-6), and poorly differentiated (Gleason score 7-10).

p53 Codon 72 Polymorphism
DNA was extracted from whole blood using a Purgene DNA Isolation Kit (Gentra System, Inc., Minneapolis, MN, USA). p53 codon 72 polymorphism was determined using PCR-RFLP as described in a previous study (31). Briefly, ~150 ng DNA sample was amplified with two primers: 5'-TTG CCG TCC CAA GCA ATG GAT GA-3' (forward) and 5'-TCT GGG AAG GGA CAG AAG ATG AC-3' (reverse; Perkin-Elmer, Taipei, Taiwan). Amplification was performed by initial denaturation at 94°C for 5 minutes, followed by 35 cycles at 94°C for 40 seconds, 68°C for 30 seconds, 72°C for 40 seconds, and a final extension at 72°C for 10 minutes. The PCR product was digested using five units of BstUI (New England Biolabs, Beverly, MA). When BstUI restriction site (Arg allele) was present, the 199-bp fragment was digested into two 113-bp and 86-bp fragments. The Pro allele was not cleaved by BstUI, and had a single band of 199 bp. The heterozygous genotype (Arg/Pro) had three bands (199, 113, and 86 bp; Fig. 1).



View larger version (17K):
[in this window]
[in a new window]
  		Figure 1. The PCR-RFLP analyses and direct-sequence result of p53 codon 72 (A) and p21 codon 31 (B) polymorphisms. A. p53 codon 72 polymorphism, the Pro allele was not cleaved by BstUI and had a single band with a fragment of 199 bp. The Arg allele was cleaved by BstUI and yielded two small fragments (113 and 86 bp). The heterozygote had three bands. B. p21 codon 31 polymorphism, AGC-to-AGA change which resulted in an amino acid substitution from serine (Ser) to arginine (Arg) and loss of a BlpI cut site. RFLP product showed digested fragments (AGC, Ser/Ser, 183 and 89 bp), an undigested fragment (AGA, Arg/Arg, 272 bp) and a heterozygous form (Ser/Arg, 272, 183 and 89 bp).

 
p21 Codon 31 Polymorphism
Polymorphism in p21 codon 31 was also determined by PCR-RFLP (32). Approximately 150 ng of DNA sample were amplified with two primers: 5'-GTC AGA ACC GGC TGG GGA TG-3' (forward), and 5'-CTC CTC CCA ACT CAT CCC GG-3' (reverse; Perkin-Elmer). Amplification was performed by initial denaturation at 94°C for 5 minutes, followed by 35 cycles at 94°C for 40 seconds, 60.3°C for 30 seconds, 72°C for 40 seconds, and a final extension at 72°C for 10 minutes. Final PCR product was digested by BlpI. The Ser alleles with BlpI site generated two 89-bp and 183-bp fragments. The Arg allele which lacked a BlpI site yielded a 272-bp fragment (Fig. 1).

All genotypes were confirmed by direct sequencing at the start of genotyping (Fig. 1). We included one positive control and one negative control sample in each genotyping set (~10 samples). The positive control sample was included to confirm complete digestion of the PCR product by restriction enzymes. The negative control was placed with the same reagents as those used with actual samples with the exception of DNA templates.

Statistical Analysis
Distribution of demographic characteristics and substance use was examined using {chi}2 statistics. For genotypes, the Hardy-Weinberg equilibrium tests were analyzed first. The associations between diseases and genotypes were assessed by calculating the OR and 95% CI. The Statistical Package for the Social Sciences software version 10.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. A two-sided P value < 0.05 was considered statistically significant.

The frequencies of p53 Pro/Pro and p21 Arg/Arg among the general male population in Taiwan were 21.0% and 22.7%, respectively (33, 34). Assuming detection of a significantly increased risk of 2.0-fold in the group with variant genotypes of p53 Pro/Pro and p21 Arg/Arg, the present study had at least 80% power to detect the two-sided 0.05 level of significance in 200 cases and 200 controls.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The demographic and clinical characteristics of prostate cancer cases, BPH and controls are shown in Table 1. The mean age (± SD) for patients with prostate cancer, BPH, and controls were 72.2 (± 7.7), 65.8 (± 8.5) and 72.2 (± 6.6), respectively. In the 200 prostate cancer cases, 128 (64.0%) cases were from Kaohsiung Veterans General Hospital, and 72 (36%) cases were from the Kaohsiung Medical University Hospital. The demographic characteristics, including height, weight, body mass index, education level, cigarette smoking, alcohol drinking, and areca chewing were not significantly different among case, BPH, and control patients. Out of 200 cancer cases, 96 (48.5%) were localized, and the histologic findings of 178 cancer cases (89.0%) were moderately or poorly differentiated.


View this table:
[in this window]
[in a new window]
  		Table 1. Demographic characteristics of prostate cancer cases, BPH and controls

 
Table 2 shows the frequencies of p53 and p21 genotypes in prostate cancer cases, BPH, and controls. Frequencies of Arg/Arg, Arg/Pro and Pro/Pro in p53 among controls were 84 (34.0%), 109 (44.1%), and 54 (21.9%), respectively. The frequency of the Pro alleles was 56.1%. Frequencies of the Ser/Ser, Ser/Arg and Arg/Arg in p21 among controls were 76 (30.8%), 119 (48.2%), and 52 (21.1%), respectively. Frequency of the Arg alleles was 45.1%. The distribution of different genotypes in both p53 and p21 polymorphisms among 247 controls closely conformed to expected Hardy-Weinberg frequencies ({chi}2 = 1.389, df = 2, P = 0.499; {chi}2 = 0.074, df = 2, P = 0.964, respectively).


View this table:
[in this window]
[in a new window]
  		Table 2. p53 Codon 72 and p21 codon 31 genotypes frequency and genotype-based OR in prostate cancer cases, BPH and controls

 
In the prostate cancer cases, the frequencies of p21 Ser/Ser, Ser/Arg and Arg/Arg were 52 (26.0%), 85 (42.5%), and 63 (31.5%); in the BPH patients, they were 48 (26.5%), 82 (45.3%), and 51 (28.2%); and in controls, they were 76 (30.8%), 119 (48.2%), and 52 (21.1%), respectively. The frequencies between the cases and controls were significantly different ({chi}2 = 6.347, df = 2, P = 0.042). After adjusting for other potential covariates (age, body mass index, educational level, cigarette smoking, alcohol drinking, and areca chewing), subjects who carried Arg/Arg were found to have a 1.78-fold increased risk (95% CI, 1.06-3.01, P = 0.029) of developing prostate cancer compared with those who carried Ser/Ser. In the BPH group, subjects who carried Arg/Arg were also found to have an increased risk of developing BPH compared with those carrying Ser/Ser, although this difference did not reach statistical significance (OR, 1.79; 95% CI, 0.97-3.29, P =0.062).

Frequencies of Arg/Arg, Arg/Pro and Pro/Pro in p53 were 66 (33.0%), 92 (46.0%), 42 (21.0%) in the prostate cancer cases, 62 (34.3%), 77 (42.5%), 42 (23.2%) in the BPH patients, and 84 (34.0%), 109 (44.1%), 54 (21.9%) in the controls, respectively. There were no significant differences in the frequencies among the cases and control patients ({chi}2 = 0.158, df = 2, P = 0.924). After adjusting for other potential covariates, subjects who carried Pro/Pro were not associated with increased risk of developing prostate cancer (OR, 1.01; 95% CI, 0.60-1.71, P = 0.960) or BPH (OR, 0.96; 95% CI, 0.53-1.74, P = 0.900) compared with those with Arg/Arg (Table 2). The frequencies of p53 and p21 genotypes between prostate cancer and BPH were not significantly different ({chi}2 = 0.510, df = 2, P = 0.775 for p53; and {chi}2 = 0.531, df = 2, P = 0.767 for p21, respectively).

When dichotomized by median age of 72 years in the prostate cancer cases, the association of p21 Arg/Arg and prostate cancer risk was found to be slightly increased among subjects who were 72 years old and below (Arg/Arg versus Ser/Arg and Ser/Ser: OR, 2.13; 95% CI, 1.16-3.92, P = 0.015; Table 3). In contrast, the effect of p21 Arg/Arg did not reach statistical significance among subjects over 72 years old (OR, 1.45; 95% CI, 0.76-2.77, P = 0.258). However, no significant synergistic effect was noted between age (≤ 72 versus > 72) and p21 polymorphism (Arg/Arg versus Ser/Arg and Ser/Ser; P = 0.566). The above results for the association between p53 polymorphism and prostate cancer risk remained insignificant (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 3. Distribution of p21 codon 31 polymorphism among prostate cancer cases and controls stratified by age

 
Table 4 shows the association between genotypes and prostate cancer risk stratified by disease stage and pathologic grade. The effect of p21 Arg/Arg on prostate cancer risk was found to be significant for localized disease and marginally significant for locally advanced disease (Arg/Arg versus Ser/Arg and Ser/Ser: OR, 1.96; 95% CI, 1.15-3.35 and OR, 1.91; 95% CI, 1.00-3.67). No significant results were found in bone metastasis disease of prostate cancer. Stratified by pathologic grade, the p21 Arg/Arg genotype was found to be associated with significantly increased risk for moderately differentiated prostate cancer (OR, 2.04; 95% CI, 1.17-3.53), but p21 Arg/Arg was not found to be associated with either poorly differentiated or well differentiated prostate cancer. Similar insignificant results were found between p53 polymorphism and clinical/pathological features of prostate cancer (Table 4).


View this table:
[in this window]
[in a new window]
  		Table 4. p21 codon 31 and p53 codon 72 polymorphisms in prostate cancer cases between different disease stages and pathologic grades

 
When stratifying the BPH group by the mean prostate volume of 49.8 mL (about 50 mL) as the cut point (> 50 mL versus ≤ 50 mL) and comparing it with that of the controls, we found a significant association between p21 Arg/Arg and large prostate volume (> 50 mL) of BPH risk (Arg/Arg versus Ser/Ser: OR, 2.29; 95% CI, 1.07-4.88; Table 5), although no similar significance was present in small prostate volume (≤ 50 mL) of BPH risk. Again, no significant association was noted between p53 polymorphism and different volumes of BPH risk.


View this table:
[in this window]
[in a new window]
  		Table 5. Distribution of p21 codon 31 and p53 codon 72 polymorphisms among BPH and controls stratified by prostate volume

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Few studies have investigated the effect of p53 codon 72 polymorphism on prostate cancer risk (7, 35). In the study of a small subset of 28 Japanese men with prostate cancer and 56 controls, Wu et al. (35) found no association between prostate cancer and p53 codon 72 polymorphism ({chi}2 = 0.448, P = 0.799). However, due to the small sample size, the definite insignificant results could not be drawn. Subsequently, in a case-control study of 115 patients with prostate cancer and 181 male controls, Henner et al. (7) found men with Pro/Pro to have a significantly lower risk of prostate cancer (OR, 0.14; 95% CI, 0.03-0.71, P = 0.017) than those with Arg/Arg. However, there may have been selection bias in the control subjects in their study, with the distribution of p53 codon 72 genotypes violating the rule of Hardy-Weinberg equilibrium. In the present study, the frequency of p53 codon 72 genotypes among the 247 male controls closely conformed to Hardy-Weinberg equilibrium, although we did not find any significant associations between p53 codon 72 polymorphism and disease risk of prostate cancer or BPH. Our findings suggest that p53 codon 72 polymorphism may not influence the development of prostate cancer or BPH.

For p21 codon 31 polymorphism, the present study found that subjects with Arg/Arg had a 1.78-fold increased risk of developing prostate cancer compared with those with Ser/Ser. The increased risk was slightly stronger (2.13-fold) in men aged 72 years old and younger. To our knowledge, our study is the first to show a significant association between p21 codon 31 polymorphism and prostate cancer risk.

Numerous studies have suggested that p21 is involved in the carcinogenesis and progression of prostate cancer. Several immunohistochemical studies have shown the expression of p21 to be associated with the clinical outcome of prostate cancer and the progression to androgen-independent prostate cancer (12 -16). In a clinical study of prostate cancer specimens, Facher et al. (36) found that 9 (16.7%) of 54 prostate cancer samples had p21 Arg alleles, a proportion that was significantly higher than that found in the 10 (9.1%) of 110 controls.

The p21 codon 31 variant lies within the DNA-binding zinc finger motif (37, 38), suggesting that this polymorphism may encode functionally distinct proteins, but the exact mechanism of how p21 codon 31 polymorphism affects prostate cancer remains unclear. A transfection study in a lung cancer cell line has showed no significant difference between the tumor suppressor abilities of the p21 Ser and Arg alleles (39). Also, in vitro studies using CDK-cyclin kinase assays have reported that both p21 Ser and Arg alleles have similar growth-inhibitory abilities (25, 40). Alternatively, the significant effect of p21 codon 31 polymorphism in the present study may be due to a linkage with other potentially functional polymorphisms that were not examined in this study. Mousses et al. (17) reported that p21 Ser to Arg substitution at codon 31 is strong linkage with p21 C-to-T transition located in 20 bp downstream from the stop codon (the 3'-untranslated region site). Recently, Kibel et al. (41) studied the p21 C-to-T polymorphism in the 3'-untranslated region among 96 patients with prostate cancer and 106 male controls in the United States. They found subjects with CT and TT genotypes to have a significantly higher risk of advanced prostate cancer than those with CC genotype (OR, 2.24; 95% CI, 1.02-4.95). Interestingly, this significant finding was strengthened (OR, 2.33; 95% CI, 0.92-5.96) in a younger age group (≤ the median age at diagnosis of 66 years). Because p21 "CT and TT" genotypes have been closely linked with p21 Arg allele at codon 31, our results were similar to the findings of Kibel et al. (41), although we did not find the significant synergistic interaction between age (≤ 72 versus > 72) and p21 polymorphism (Arg/Arg versus Ser/Arg and Ser/Ser; P = 0.566). Ours and the Kibel study were molecular epidemiologic studies. Future studies need to clarify the functional effects of p21 polymorphisms in codon 31 and the 3'-untranslated region on prostate cancer risk.

The present study also found p21 Arg/Arg to be significantly associated with localized/locally advanced prostate cancer, but not with prostate cancer with bone metastasis (Table 4). Also, this significant association was noted in moderately differentiated disease (OR, 2.04; 95% CI, 1.17-3.53), but not in poorly differentiated disease (OR, 1.49; 95% CI, 0.85-2.61). Although a correlation has been found between expression of p21 and clinical severity of prostate cancer (12, 13), how p21 codon 31 polymorphism affects the clinical/pathological features of prostate cancer remains unknown. One explanation was that the number of cases in our study was relatively small in the subclassification analysis; another possible explanation was that other genetic alterations, except p21codon 31 genotypes, may play an important role in the progression and metastasis of prostate cancer. Nevertheless, whether the p21 codon 31 polymorphism had phenotypic effects on prostate cancer deserves further investigation.

A significant association was found between the p21 Arg/Arg and BPH with large prostate volume (> 50 mL). Men with Arg/Arg had a 2.29-fold increased risk of large-prostate volume BPH, compared with those with the Ser/Ser genotype (Table 5). BPH is characterized by an increased number of epithelial and stromal cells in the periurethral area of the prostate. The increased number of cells may be due either to epithelial and stromal proliferation or to impaired programmed cell death, leading to cellular accumulation (42). p21 is a mediator of the effect of p53 on G1 arrest in the cell cycle and also interacts with proliferating cell nuclear antigen to control DNA replication (43). Expression of p21 has been reported in BPH (44). Because the alteration p21 gene also interrupts the cell cycle and influences the progression of apoptosis (45), we propose that gene alteration in p21 could cause an imbalance between prostate cell proliferation and apoptosis, and may also participate in the pathogenesis of BPH.

In the present study, patients with BPH, and prostate-specific antigen levels above > 4 ng/mL, were screened for cancer by prostate biopsy to avoid undetectable, occult prostate tumor. Therefore, the misclassification of outcome should be reduced. In conclusion, the p21 codon 31, but not the p53 codon 72, polymorphism was associated prostate cancer risk, especially in younger men (≤ 72 years). p21 codon 31 polymorphism was also associated with disease stage and pathologic grade. In addition, the p21 Arg/Arg was related with the risk of BPH with large prostate volume (> 50 mL). Furthermore, in vitro and in vivo studies are needed to elucidate the functional effect of p21 codon 31 polymorphism on the development of prostate cancer or BPH.


   Footnotes
 
Grant support: Supported in part by grants from Taiwan's National Science Council,Taipei, Taiwan (NSC 91-2320-B-037-024 and NSC 92-2320-B-037-039).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2/17/04; revised 5/ 2/04; accepted 6/ 3/04.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453–6.[CrossRef][Medline]
  2. Hollstein M, Sideransky D, Volgelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49–53.[Abstract/Free Full Text]
  3. Gumerlock PH, Chi SG, Shi XB, et al. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst 1997;89:66–71.[Abstract/Free Full Text]
  4. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657–69.[Abstract/Free Full Text]
  5. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961–3.[Abstract/Free Full Text]
  6. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092–100.[Abstract/Free Full Text]
  7. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM. Association of codon 72 polymorphism of the p53 with lower prostate cancer risk. Prostate 2001;49:263–6.[CrossRef][Medline]
  8. Oesterling JE. The origin and development of benign prostatic hyperplasia. An age-dependent process. J Androl 1991;12:348–55.[Abstract/Free Full Text]
  9. Meyers FJ, Chi SG, Fishman JR, deVere White RW, Gumerlock PH. p53 mutations in benign prostatic hyperplasia. J Natl Cancer Inst 1993;85:1856–8.[Free Full Text]
  10. Zhang XH, Sakamoto H, Takenaka I. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Br J Urol 1996;77:441–4.[Medline]
  11. Xiong Y, Hannon GJ, Zhang HD, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinase, Nature 1993;366:701–4.
  12. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate 1999;39:8–15.[CrossRef][Medline]
  13. Matsushima H, Sasaki T, Goto T, et al. Immunohistochemical study of p21WAF1 and p53 protein in prostate cancer and their prognostic significance. Hum Pathol 1998;29:778–83.[CrossRef][Medline]
  14. Omar EA, Behlouli H, Chevalier S, Aprikian AG. Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 2001;49:191–9.[CrossRef][Medline]
  15. Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21WAF1 and P27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000;6:1896–9.[Abstract/Free Full Text]
  16. Fizazi K, Martinez LA, Sikes CR, et al. The association of p21(WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin Cancer Res 2000;8:775–81.
  17. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 1995;4:1089–92.[Abstract/Free Full Text]
  18. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum Hered 1996;46:221–5.[Medline]
  19. Roh J, Kim M, Kim J, et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett 2001;165:59–62.[CrossRef][Medline]
  20. Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A. Waf-1 (p21) and p53 polymorphism in breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:127–30.[Abstract/Free Full Text]
  21. Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 2002;23:311–5.[Abstract/Free Full Text]
  22. Tsai MH, Chen WC, Tsai FJ. Correlation of p21 gene codon 31 polymorphism and TNF-{alpha} gene polymorphism with nasopharyngeal carcinoma. J Clin Lab Anal 2002;16:146–50.[CrossRef][Medline]
  23. Wu MT, Wu DC, Hsu HK, Kao EL, Yang CH, Lee JM. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett 2003;201:175–80.[CrossRef][Medline]
  24. Su L, Liu G, Zhou W, et al. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:174–5.[Free Full Text]
  25. Sun Y, Hildesheim A, Li H, et al. No point mutation but a codon 31ser->arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev 1995;4:261–7.[Abstract]
  26. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57.[Medline]
  27. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–71.[CrossRef][Medline]
  28. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995;46:34–40.[CrossRef][Medline]
  29. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1987;145:984.
  30. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58–64.[Medline]
  31. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9: 1037–42.
  32. Li YJ, Kaurent-Puig P, Salmon RJ, Thomas G, Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 1995;10:599–601.[Medline]
  33. Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999;5:129–34.[Abstract/Free Full Text]
  34. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 2000;91:9–15.[Medline]
  35. Wu WJ, Kakehi Y, Habuchi T, et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 1995;86:730–6.[Medline]
  36. Facher EA, Becich MJ, Deka A, Law JC. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 1997;79:2424–9.
  37. EI-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817–25.[CrossRef][Medline]
  38. Huppi K, Siwarski D, Dosik J, et al. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (WAF1). Oncogene 1994;9:3017–20.[Medline]
  39. Chedid M, Michieli P, Lengel C, Huppi K, Givol DA. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 1994;9:3021–4.[Medline]
  40. Terry LA, Boyd J, Alcorta D, et al. Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines. Mol Carcinog 1996;16:221–8.[CrossRef][Medline]
  41. Kibel AS, Suarez BK, Belani J, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003;63:2033–6.[Abstract/Free Full Text]
  42. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. In: Walth PC, Retik AB, Stamey TA, Vaughan ET Jr, editors, Campell's Urology. Philadelphia (PA): Saunders; 2002. p. 1297–336.
  43. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574–8.[CrossRef][Medline]
  44. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur Cytokine Netw 2001;12:654–63.[Medline]
  45. Zhang Y, Fujita N, Tsuruo T. Caspase-mediated cleavage of p21 Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999;18:1131–8.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S.-P. Huang, C.-Y. Huang, J.-S. Wang, C.-C. Liu, Y.-S. Pu, H.-J. Yu, C.-C. Yu, T. T. Wu, C.-H. Huang, W.-J. Wu, et al.
Prognostic Significance of p53 and X-ray Repair Cross-complementing Group 1 Polymorphisms on Prostate-Specific Antigen Recurrence in Prostate Cancer Post Radical Prostatectomy
Clin. Cancer Res., November 15, 2007; 13(22): 6632 - 6638.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, S.-P.
Right arrow Articles by Huang, C.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, S.-P.
Right arrow Articles by Huang, C.-H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation